Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2013 Financial Results

  Impax Laboratories Schedules Conference Call and Webcast for First Quarter
  2013 Financial Results

Business Wire

HAYWARD, Calif. -- April 03, 2013

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will
release its first quarter 2013 financial results on Wednesday, May 1, 2013,
after the close of the U.S. financial markets. The Company will host a
conference call and live webcast with the investment community at 4:30 p.m.,
Eastern Time on May 1, 2013.

The financial results and live webcast will be accessible through the Investor
Relations section of the Company's Web site, www.impaxlabs.com.

To access the call through a conference line, dial (877) 356-3814 (in the
U.S.) and (706) 758-0033 (international callers). The conference ID is
32064217.

A replay of the conference call will be available for seven days shortly after
the call. To access the replay, dial (855) 859-2056 (in the U.S.) and (404)
537-3406 (international callers). The access code for the replay is 32064217.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty
pharmaceutical company applying its formulation expertise and drug delivery
technology to the development of controlled-release and specialty generics in
addition to the development of central nervous system disorder branded
products. Impax markets its generic products through its Global
Pharmaceuticals division and markets its branded products through the Impax
Pharmaceuticals division. Additionally, where strategically appropriate, Impax
develops marketing partnerships to fully leverage its technology platform and
pursues partnership opportunities that offer alternative dosage form
technologies, such as injectables, nasal sprays, inhalers, patches, creams and
ointments. Impax Laboratories is headquartered in Hayward, California, and has
a full range of capabilities in its Hayward, Philadelphia, Pennsylvania and
Taiwan facilities. For more information, please visit the Company's Web site
at: www.impaxlabs.com.

Contact:

Impax Laboratories, Inc.
Mark Donohue
Sr. Director, Investor Relations and Corporate Communications
215-558-4526
www.impaxlabs.com